March 2, 2026 · Form 4 insider transaction
Stonehouse Jon P sold 305,995 shares of BioCryst Pharmaceuticals, Inc. at $8.64 per share, a transaction worth $2.64M. The trade was recorded as disposition to the issuer under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 1 day after the transaction.
This transaction was made pursuant to a plan adopted by the reporting person on November 28, 2022, as modified on May 13, 2024 and further modified on May 29, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The options were originally granted to the reporting person on May 23, 2016 and would have expired on May 23, 2026. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.; The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.54 to $8.81. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.